The retinoblastoma gene family: its role in cancer onset and progression

Bibliography

• HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 1 00 :57–70.
   Google Scholar
• ••An excellent review on alteration of regulatory circuitsessential for transforming normal cells into malignant cells.
   Google Scholar
• RENAN MJ: How many mutations are required for tumorogenesis? Implications from human cancer data. Mol. Carcinogenesis (1993) 7:139–146.
   PubMed Web of Science ®Google Scholar
• BERGERS G, HANAHAN D, COUSSES LM: Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorige-nesis. Int. j Dev. Biol. (1998). 42:995–1002.
   PubMed Web of Science ®Google Scholar
• KINZLER KW, VOGELSTEIN B: landscaping the cancer terrain. Science (1998) 280:1036–1037.
   PubMed Web of Science ®Google Scholar
• KNUDSON AG: Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA (1971) 68:820–823.
   PubMed Web of Science ®Google Scholar
• HAHN WC, COUNTER CM, LUNDBERG AS et al.: Creation of human tumor cells with defined genetic elements. Nature (1999) 400:464-468. 7.Molecular Oncology. Bishop JM, Weinberg RA (Eds.), Scientific American, Inc., New York, USA (1996).
   Google Scholar
• •An interesting book on molecular mechanisms which are involved in malignant transformation.
   Google Scholar
• LASKOD, CAVENEE W, NORDENSKJOLD M: loss of constitutional heterozygosity in human cancer. Ann. Rev. Genet. (1991) 25:281–314.
   PubMed Web of Science ®Google Scholar
• ZHU L, VAN DEN HEUVEL S, HELIN K et al.: Inhibition of cell proliferation by p107, a relative of the retinoblas-toma protein. Genes Dev. (1993) 7:1111–1125.
   PubMed Web of Science ®Google Scholar
• CLAUDIO PP, HOWARD CM, BALDI A et al.: p130/pRb2 has growth suppressive properties similar to yet distinctive from those of retinoblastoma family members pRb and p1 0 7. Cancer Res. (1 9 9 4) 54:5556-5560.
   Google Scholar
• •First description of pRb2/p130 growth suppressive proper-ties and of possible genetic alterations in nasopharyngeal cancer.
   Google Scholar
• STAROSTIK P, CHOW KNB, DEAN DC: Transcriptional repression and growth suppression by the p107 pocket protein. Mol Cell. Biol. (1996) 16:3606–3614.
   PubMed Web of Science ®Google Scholar
• •This paper is focused on growth suppressive properties and transcriptional repression activity of p107.
   Google Scholar
• CLAUDIO PP, HOWARD CM, PACILIO C et al.: Mutations in the retinoblastoma-related gene Rb2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res. (2000) 60:372–382.
   PubMed Web of Science ®Google Scholar
• ••This paper shows for the first time the possibility to usepRb2/p130 in lung cancer gene therapy.
   Google Scholar
• HUANG HJ, YEE JK, SHEW JY et al.: Suppression of the neoplastic phenotype by replacement of the Rb gene in human cancer cells. Science (1988) 242:1563–1566.
   PubMed Web of Science ®Google Scholar
• ••An interesting report on the ability of pRb/p105 to inhibit themalignant phenotype.
   Google Scholar
• CAVENEE WK, HANSEN MF, NORDENSKJOLD M et al.: Genetic origin of mutations predisposing to retino-blastoma. Science (1985) 228:501–503.
   PubMed Web of Science ®Google Scholar
• BALDI A, BOCCIA V, CLAUDIO PP, DE LUCA A, GIORDANO A: Genomic structure of the human retinoblastoma-related Rb2/p130 gene. Proc. Natl. Acad. Sci. USA (1996.) 93:4629–4632.
   PubMed Web of Science ®Google Scholar
• YEUNG RS, BELL DW, TESTA JR et al.: The retinoblastoma-related gene, Rb2, maps to human chromosomes 16q12 and rate chromosome 19. Oncogene (1993) 8:3465–3458.
   PubMed Web of Science ®Google Scholar
• WEINBERG RA: Tumor suppressor genes. Science (1991) 254:1138–1145.
   PubMed Web of Science ®Google Scholar
• MASCIULLO V, KHALILI K, GIORDANO A: The Rb familyof cell cycle regulatory factors: clinical implications. Int. J. Oncol. (2000) 17:897–902.
   PubMed Web of Science ®Google Scholar
• SANG N, BALDI A, GIORDANO A: The roles of tumor suppressors pRb and p53 in cell proliferation and cancer. Mol. Cell. Diff (1995) 3:1–29.
   Google Scholar
• •A comprehensive review on the involvement of both pRb/p105 and p53 in the control of cell fates.
   Google Scholar
• BIGGS PJ, WOOSTER R, FORD D et al: Familial cylindro-matosis (turban tumor syndrome) gene localised to chromosome 16q12-q13: evidence for its role as tumor suppressor gene. Nature Genet. (1995) 11:441-443.
   Google Scholar
• CINTI C, CLAUDIO PP, HOWARD CM et al: Genetic altera-tion disrupting the nuclear localization of the retinoblastoma-related gene of Rb2/p130 in human tumor cell lines and primary tumors. Cancer Res. (2000) 60:383–389.
   PubMed Web of Science ®Google Scholar
• CINTI C, LEONCINI L, NWONGO A et al: Genetic altera-tions of the retinoblastoma related gene Rb2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes. Am. J. Pathol (2000) 156:751–760.
   PubMed Web of Science ®Google Scholar
• CLAUDIO PP, HOWARD CM, FU Y et al: Mutations in theretinoblastoma-related gene Rb2/p130 in primary nasopharyngeal carcinoma. CancerRes. (2000) 60:8–12.
   Web of Science ®Google Scholar
• LEVINE AJ: The tumor suppressor genes. Ann. Rev.Biochem. (1993) 62:623–651.
   PubMed Web of Science ®Google Scholar
• WEINBERG RA: The retinoblastoma protein and cell cycle control. Cell (1995) 81:323–330.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the role of pRb/p105 in cell cyclecontrol.
   Google Scholar
• PAGGI MG, BALDI A, BONETTO F, GIORDANO A: Retino-blastoma protein family in cell cycle and cancer. A review. J. Cell. Biochem. (1996) 62:418–430.
   PubMed Web of Science ®Google Scholar
• MAYOL X, GRANA X, BALDI A, SANG N, HU Q, GIORDANO A: Cloning of a new member of the retino-blastoma gene family (pRb2) which binds to the F1A transforming domain. Oncogene (1993) 8:2561–2566.
   PubMed Web of Science ®Google Scholar
• EWEN ME, XING EW, LAWRENCE JB, LIVINSTON D: Molecular cloning, chromosomal mapping and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell (1991) 66:1155–1164.
   PubMed Web of Science ®Google Scholar
• HANNON GJ, DEMERICK D, BEACH D: Isolation of theRb-related p130 through its interaction with cdk2 and cyclins. Genes Dev. (1993) 7:2378–2391.
   PubMed Web of Science ®Google Scholar
• LI Y, GRAHAM C, LACY S, DUNCAN AMV, WHYTE P: Theadenovirus F1A-associated 130-kd protein is encoded by a member of the retinoblastoma gene family and physically interacts with cyclins A and E in a temporally distinct manner. Genes Dev. (1993) 7:2366–2377.
   PubMed Web of Science ®Google Scholar
• LEE JO, RUSSO AA, PAVLETICH NP: Structure of theretinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature (1998) 391:859–865
   PubMed Web of Science ®Google Scholar
• TAYA Y: Rb kinase and Rb-binding proteins: new pointof view. Trends Biol. ScL (1997) 21:14–17.
   Web of Science ®Google Scholar
• PURI PL, MACLACHLAN TK, LEVRERO M, GIORDANO A: The intrinsic cell cycle: from yeast to mammal. In: The Molecular Basis of Cell Cycle and Growth Control. Stein GS, Baserga R, Giordano A, Denhardt DT (Eds.), Wiley-Liss, New York, USA (1999):15–79.
   Google Scholar
• •An interesting book on mechanisms controlling cell cycle and cell growth.
   Google Scholar
• DYSON N: The regulation of E2F by pRB-family proteins. Genes Dev. (1998) 12:2245–2262.
   PubMed Web of Science ®Google Scholar
• LUO RX, POSTIGO AA, DEAN DC: Rb interacts with histone deacetylase to repress transcription. Cell (1998) 92:463–473.
   PubMed Web of Science ®Google Scholar
• •Demonstration of the association between pRb/p105 and HDAC1 to repress the E2F-regulated genes by changing chromatin structure.
   Google Scholar
• BREHM A, MISKA EA, MCCANCE DJ et al: Retinoblastomaprotein recruits histone deacetylase to repress transcription. Nature (1998) 391 :597–601.
   PubMed Web of Science ®Google Scholar
• STIEGLER P, DE LUCA A, BAGELLA L, GIORDANO A: TheCOOH-terminal region of pRb2/p130 binds to histone deacetylase 1 (HDAC1), enhancing transcriptional repression of the E2F-dependent cyclin A promoter. Cancer Res. (1998) 58:5049–5052.
   PubMed Web of Science ®Google Scholar
• •First description of molecular analysis of the interaction between pRb2/p130 and HDAC1 helping to explain the mechanisms of pRb2/p130 action in transcriptional control.
   Google Scholar
• MAGNAGHI-JAULIN L, GROISMAN R, NAGUIBNEBA I et Retinoblastoma protein represses transcription by recruiting histone deacetylase. Nature (1998) 391:601–604.
   PubMed Web of Science ®Google Scholar
• WHITAKER LL, SU H, BASKARAN R, KNUDSEN ES, WANG JY: Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell. Biol. (1998) 18:4032–4042.
   PubMed Web of Science ®Google Scholar
• HU Q, DYSON N, HARLOW E: The regions of the retino-blastoma protein needed for binding to adenovirus F1A or SV40 large T antigen are common sites for mutations. EMBO J (1990) 9:1147–1155.
   PubMed Web of Science ®Google Scholar
• HUANG S, WANG N-P, TSENG BY, LEE WH, LEE EH-HP: Two distinct and frequently mutated regions of retino-blastoma protein are required for binding to SV40 T antigen. EMBO J (1990) 9:1815–1822.
   PubMed Web of Science ®Google Scholar
• DE LUCA A, MACLACHLAN TK, BAGELLA L et al: Aunique domain of pRb2/p130 acts as inhibitor of cdk2 kinase activity. J Biol. Chem. (1997) 272:20971–20974.
   PubMed Web of Science ®Google Scholar
• CHU WM, WANG Z, ROEDER RG, SCHMID CW J: RNA polymerase III transcription repressed by Rb through its interactions with TFIIIB and TFIIIC2. j Biol Chem. (1997) 272:14755–14761.
   PubMed Web of Science ®Google Scholar
• WHITE RJ, TROUCHE D, MARTIN K, JACKSON SP, KOUZARIDES T: Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature (1996) 382:88–90.
   PubMed Web of Science ®Google Scholar
• SUTCLIFFE JE, CAIRNS CA, MCLEES A et al.: RNApolymerase III transcription Factor IIIB is a target for repression by pocket proteins p107 and p130. Mol Biol. (1999) 19:4255–4261.
   Web of Science ®Google Scholar
• JOHNSON DG, SCHNEIDER-BROUSSARD R: Role of E2F in cell cycle control and cancer. Front Biosci. (1998) 3:D447–D458.
   Google Scholar
• ••A comprehensive review describing E2F transcriptionalactivity and its role in cell cycle control, apoptosis and cancer.
   Google Scholar
• WU CL, ZUKERBERG LR, NGWU C, HARLOW E, LEES JA: In vivo association of F2F and DP family proteins. Mol Cell. Biol. (1995) 15:2536–2546.
   PubMed Web of Science ®Google Scholar
• ADAMS PD, KAELIN WG, JR.: Transcriptional control by E2F. Semin. Can. Biol. (1995) 6:99–108.
   PubMed Web of Science ®Google Scholar
• QIAN Y, LUCKEY C, HORTON L, ESSER M, TEMPLETON DJ:Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell. Biol (1992) 12:5363–5372.
   PubMed Web of Science ®Google Scholar
• QUIN XQ, CHITTENDEN T, LIVINGSTON D, KAELIN WG: Identification of a growth suppressor domain within the retinoblastoma gene product. Genes Dev. (1992) 6:953–964.
   PubMed Web of Science ®Google Scholar
• HIEBERT SW: Regions of the retinoblastoma geneproduct required for its interaction with the E2F transcription factors are necessary for E2 promoter repression and pRb-mediated growth suppression. Mol. Cell. Biol. (1993) 13:3384–3391.
   PubMed Web of Science ®Google Scholar
• RAYCHADHURY P, BAGCHI S, DEVOTO SH et al.: Domains of the adenovirus E1A protein that are required for oncogenic activity are also required for dissociation of F2F transcription factor complex. Genes Dev. (1991) 5:1200–1211.
   PubMed Web of Science ®Google Scholar
• KAYE FJ, KRATZKE RA, GERSTER JL, HOROWITZ JM: Asingle amino acid substitution results in a retinoblas-toma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA (1990) 87:6922–6926.
   PubMed Web of Science ®Google Scholar
• HOROWITZ JM, YANDELL DW, PARK SH et al.: Pointmutational inactivation of the retinoblastoma antion-cogene. Science (1989) 243:937–940.
   PubMed Web of Science ®Google Scholar
• CHITTEDEN T, LIVINGSTON DM, KAELIN WG: The T/F1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein. Cell (1991) 65:1071–1082.
   Google Scholar
• HIEBERT SW, CHELLAPPAN SP, HOROWITS JM, NEVINSJR: The interaction of RB with F2F coincides with an inhibition of the transcriptional activity of F2F. Genes Dev. (1992) 6:177–185.
   PubMed Web of Science ®Google Scholar
• SLANSKY JE, FARNHAM PJ: Introduction to the E2Ffamily: protein structure and gene regulation. CUIT. Top. Microbic)]. Immunol. (1996) 208:1–30.
   PubMed Web of Science ®Google Scholar
• CLAUDIO PP, CAPUTI M, GIORDANO A: Gene therapymodels. The Rb2/p130 gene: the latest weapon in the war against lung cancer? Clin. Canc. Res. (2000) 6:754–764.
   PubMed Web of Science ®Google Scholar
• VAIRO G, LIVINGSTON DM, GINSBERG D: Functional interaction between F2F-4 and p130: evidence for distinct mechanisms underlying growth suppressor by different retinoblastoma protein family members. Genes Dev. (1995) 9:869–881.
   PubMed Web of Science ®Google Scholar
• GINSBERG D, VAIRO G, CHITTENDEN T et al.: E2F4, anew member of the F2F transcription factor family, interacts with p107. Genes Dev. (1994) 8:2665–2679.
   PubMed Web of Science ®Google Scholar
• MOBERG K, STARTS MA, LEES JA: E2F4 switches fromp130 to p107 and pRb in response to cell cycle reentry. Mol. Cell. Biol (1996) 16:1436–1449.
   PubMed Web of Science ®Google Scholar
• HUMANS EN, VOORHOEVE PM, BEIJERSBERGEN RL, VANVEER LJ, BERNARDS R: F2F5, a new F2F family member that interacts with p130 in vivo. Mol. Cell. Biol. (1995) 15:3082–3089.
   PubMedGoogle Scholar
• LINDEMAN GJ, GAUBATZ S, LIVINGSTON DM, GINSBERG D: The subcellular localization of F2F-4 is cell-cycle dependent. Proc. Natl. Acad. Sci. USA (1997) 94: 5095–5100.
   Google Scholar
• •An interesting paper providing a potential mechanism for E2F-4 transcription factor regulation by changes in its subcellular localisation.
   Google Scholar
• DE LA LUNA S, BURDEN MJ, LEE C-W, LA THANGUE NB: Nuclear accumulation of the E2F heterodimer regulated by subunit composition and alternative splicing of a nuclear localization signal. J Cell Sci. (1996) 109:2443–2452.
   PubMed Web of Science ®Google Scholar
• MAGAE J, WU C-L, ILLENYE S, HARLOW E, HEINTZ NH: Nuclear localization of DP and E2F transcription factors by heterodimeric patterns and retinoblastoma protein family members. J. Cell Sci. (1 9 9 6) 109:1717-1726.
   Google Scholar
• PURI PL, CIMINO L, FULCO M et al.: Regulation of E2F4 mitogenic activity during terminal differentiation by its heterodimerization partners for nuclear transloca-tion. Cancer Res. (1998) 58:1325–1331.
   PubMed Web of Science ®Google Scholar
• COBRINIK D, WHYTE P, PEEPER DS, JACKS T, WEINBERG RA: Cell cycle specific association of F2F with the p130 MA-binding protein. Genes Dev. (1993) 7: 2392–2404.
   Google Scholar
• JOHNSON DG: Regulation of F2F1 gene expression by p130 (Rb2) and D-type cyclin kin ase activity. Oncogene (1995) 11:1685–1692.
   PubMed Web of Science ®Google Scholar
• ZHU L, XIE E, CHANG LS: Differential role of two tandem F2F sites in repression of the human p107 promoter by retinoblastoma and p107 proteins. Mol. Cell. Biol. (1995) 15:3552–3562.
   PubMed Web of Science ®Google Scholar
• CHELLAPPAN SP: The F2F transcription factor: role of the cell cycle regulation and differentiation. Mol. Differ. (1994) 2:201–220.
   Google Scholar
• JOHNSON DG, CRESS WD, JAKOI L, NEVINS JR: Oncogenic capacity of the F2F1 gene. Proc. Natl. Acad. Sci. USA (1994) 91:12823–12827.
   PubMed Web of Science ®Google Scholar
• SINGH P, WONG S, HONG W: Overexpression of F2F-1 in rat embryo fibroblasts leads to neoplastic transfor-mation. EMBO J (1994) 13:3329–3338.
   PubMed Web of Science ®Google Scholar
• XU G, LIVINGSTON DM, KREK W: Multiple members of the F2F transcription factor family are the products of oncogenes. Proc. Natl. Acad. Sci. USA (1995) 92:1357–1361.
   PubMed Web of Science ®Google Scholar
• YAMASAKI L, JACKS T, BRONSON R et al.: Tumor induction and tissue atrophy in mice lacking F2F-1. Cell (1996) 85:537–548.
   PubMed Web of Science ®Google Scholar
• PIERCE AM, FISHER SM, CONTI CJ, JOHNSON DG: Deregulated expression of F2F1 induces hyperplasia and cooperates with ras in skin tumor development. Oncogene (1998) 16:1267–1276.
   PubMed Web of Science ®Google Scholar
• PIERCE AM, GIMENEZ-CONTI IB, SCHNEIDER-BROUSSARD R et al.: Increased F2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc. Natl. Acad. Sci. USA (1998) 95:8858–8863.
   PubMed Web of Science ®Google Scholar
• MORAN E: DNA tumor virus transforming proteins and the cell cycle. Curr. Opin. Genet. Dev. (1993) 3:63–70.
   PubMed Web of Science ®Google Scholar
• •An excellent review on the role of viral oncoproteins in carcinogenesis.
   Google Scholar
• DECAPRIO JA, LUDLOW JW, FIGGE J et al.: SV40 largetumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (1988) 54:275–283.
   PubMed Web of Science ®Google Scholar
• DYSON N, HOWLEY PM, MUENGER K, HARLOW E: Thehuman papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 243:934–937.
   PubMed Web of Science ®Google Scholar
• WHYTE P, BUCKOVICH KJ, HOROWITZ JM et al.: Associa-tion between an oncogene and an antioncogene: the adenovirus FIA proteins bind to the retinoblastoma gene product. Nature (1988) 334:124–127.
   PubMed Web of Science ®Google Scholar
• WHYTE P, WILLIAMSON NM, HARLOW E: Cellular targets for transformation by the adenovirus FIA proteins. Cell (1989) 56:67–75.
   PubMed Web of Science ®Google Scholar
• STUBDAL H, ZALVIDE J, DECAPRIO JA: Simian virus 40large T antigen alters the phosphorylation state of the RB-related proteins p130 and p107. j Virol (1996) 70:2781–2788.
   PubMed Web of Science ®Google Scholar
• GIORDANO A, LEE JH, SCHEPPLER JA et al.: Cell cycleregulation of histone HI kinase activity associated with the adenoviral protein EIA. Science (1991) 253:1271–1275.
   PubMed Web of Science ®Google Scholar
• SLEBO RJ, LEE MH, PLUNKETT BS et al: p53-dependentGI arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. USA (1994) 91:5320–5324.
   PubMed Web of Science ®Google Scholar
• STUBDAL H, ZALVIDE J, CAMPBEL KS et al: Inactivation of pRB-related proteins p130 and p107 mediated by the J domain of simian virus 40 large T antigen. Mol Biol (1997) 17:4979–4990.
   Web of Science ®Google Scholar
• CHEN S, PAUCHA E: Identification of the region of simian virus 40 large T antigen required for cell transformation. J Virol (1990) 64:3350–3357.
   PubMed Web of Science ®Google Scholar
• EGAN C, BAYLEY ST, BRANTON PE: Binding of the Rb1 protein to FIA products is required for adenovirus transformation. Oncogene (1989) 4:383–388.
   PubMed Web of Science ®Google Scholar
• MORAN E, ZERLER B, HARRISON TM, MATHEWS MB: Identification of separate domains in the adenovirus Fl A gene for immortalization activity and the activa-tion of virus early genes. MM. Cell. Biol. (1986) 6:3470–3480.
   Web of Science ®Google Scholar
• WHYTE P, RULEY HE, HARLOW E: Two regions of the adenovirus early reaction IA protein are required for transformation. J Virol (1988) 62:257–265.
   PubMed Web of Science ®Google Scholar
• BAGCHI S, RAYCHAUDHURI P, NEVINS JR: Adenovirus FIA proteins can dissociate heteromeric complexes involving the E2F transcription factor: a novel mechanism for EIA trans-activation. Cell (1990) 62:659–669.
   PubMed Web of Science ®Google Scholar
• NEVINS JR: F2F: a link between Rb tumor suppressorprotein and viral oncoproteins. Science (1992) 258:424–429.
   PubMed Web of Science ®Google Scholar
• KAELIN WG, EWEN ME, LIVINGSTON DM: Definition ofthe minimal simian virus 40 large T antigen and adenovirus FIA-binding domain in the retinoblatoma gene product. Mol Cell. Biol. (1990) 10:3761–3769.
   PubMed Web of Science ®Google Scholar
• DINGWALL C, LASKEY RA: Nuclear targeting sequences: a consensus? Trends Biol. Sci. (1991) 16:478–481.
   Google Scholar
• ZACKSENHAUS E, BREMNER R, PHILLIPS RA, GALLIE BL: A bipartite nuclear localization signal in the retinoblas-toma gene product and its importance for biological activity. Mol Cell. Biol. (1993) 13: 4588–4599.
   Google Scholar
• •First description of pRb/p105 nuclear localisation signal and its importance in regulating the biological activity of pRb/p105.
   Google Scholar
• THOMAS RC, EDWARS MJ, MARKS R: Translocation of the retinoblastoma gene product during mitosis. Exp. Cell Res. (1996) 223:227–232.
   PubMed Web of Science ®Google Scholar
• GRUMSTEIN M: Histone acetylation in chromatin structure and transcription. Nature (1997) 389:349–352.
   PubMed Web of Science ®Google Scholar
• WOO MS-A, SANCHEZ I, DYNLACHT BD: p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity. Mol. Cell. Biol. (1997) 17:3566–3579.
   PubMed Web of Science ®Google Scholar
• HERRMANN CH, SU LK, HARLOW E: Adenovirus FIA is associated with a serine/threonine protein kinase. Vim]. (1991) 65:5848–5859.
   Google Scholar
• KNUDSEN ES, WANG JYJ: Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J. Biol. Chem. (1996) 271:8313–8320.
   PubMed Web of Science ®Google Scholar
• SHIRODKAR S, EWEN M, DECAPRIO JA et al.: The transcription factor F2F interacts with the retinoblas-toma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell (1992) 66:157–166.
   Web of Science ®Google Scholar
• BALDI A, DE LUCA A, CLAUDIO PP et al: The Rb2/p130 gene product is a nuclear protein whose phosphoryla-tion is cell cycle regulated. J Cell. Biochem. (1995) 59:402–408.
   PubMed Web of Science ®Google Scholar
• PHILLIPS A, HUET X, PLET A et al: The retinoblastoma protein is essential for cyclin A repression in quiescent cells. Oncogene (1998) 16:1373–1381.
   PubMed Web of Science ®Google Scholar
• DONG F, CRESS WD JR, AGRAWAL D, PLEDGER WJ: The role of cyclin D3-dependent kinase in the phosphory-lation of p130 in mouse BALB/c 313 fibroblasts./ Biol. Chem. (1998) 273:6190–6195.
   PubMed Web of Science ®Google Scholar
• BONETTO F, FANCIULLI M, BATTISTA T et al: Interaction between the pRb2/p130 C-terminal domain and N-terminal portion of cyclin D3. J. Cell Biochem. (1999) 75:698–709.
   PubMed Web of Science ®Google Scholar
• DOWDY SF, HINDS PW, LOUIS K et al: Physical interac-tion of retinoblastoma protein with human D cyclin. Cell (1993) 73:499–511.
   PubMed Web of Science ®Google Scholar
• CLAUDIO PP, DE LUCA A, HOWARD CM et al: Functional analysis of pRb2/p130 interaction with cyclins. Cancer Res. (1996) 56:2003–2008.
   PubMed Web of Science ®Google Scholar
• BARTEK J, BARTKOVA J, LUKAS J: The retinoblastoma protein pathway and the restriction point. CUIT. Opin. Cell Biol. (1996) 8:805–814.
   PubMed Web of Science ®Google Scholar
• WHYTE P: The retinoblastoma protein and its relatives. Semin. Cancer. Biol. (1995) 6:83–90.
   PubMed Web of Science ®Google Scholar
• HOWARD CM, CLAUDIO PP, DE LUCA A et al.: Inducible pRb2/p130 expression and growth-suppressive mechanisms: evidence of a pRb2/p130, p27kip1 and cyclin Enegative feedback regulatory loop. Cancer Res. (2000) 60:2737–2744.
   PubMed Web of Science ®Google Scholar
• SELLERS WR, KAELIN WG, JR.: Role of the retinoblas-toma protein in the pathogenesis of human cancer. J. Clin. Oncol. (1997) 15:3301–3312.
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review on the role of pRb/p105 in humancancer pathogenesis.
   Google Scholar
• SERRANO M, LEE HW, CHIN L et al: Role of the INK4a locus in tumor suppression and cell mortality. Cell (1996) 85: 27–37.
   Google Scholar
• DENG C, ZHANG P, HARPER P et al: Mice lacking p21 CIP/WAF1 undergo normal development, but are defective in the G1 checkpoint control. Cell (1995) 82:675–684.
   PubMed Web of Science ®Google Scholar
• FERO ML, RIVKIN M, TASCH M et al.: A syndrome of multiorgan hyperplasia with features of gigantism tumorigenesis and female sterility in p27Kip1-deficent mice. Cell (1996) 85:733–744.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA K, ISHIDA N, SHIRANE M et al.: Mice lacking p27KiP1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell (1996) 85:707–720.
   PubMed Web of Science ®Google Scholar
• HARBOUR JW, LUO RX, DEI SANTI A, POSTIGO AA, DEAN DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 98:859–869.
   PubMed Web of Science ®Google Scholar
• ••This paper sheds light on intramolecular interactions amongpRb/p105, cdks and HDAC1 during the cell cycle.
   Google Scholar
• SHERR CJ, ROBERTS JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. (1 9 9 5) 9:1149-1463.
   Google Scholar
• ZHU L, HARLOW E, DYNLACHT BD: p107 uses a p21CIP-related domain to bind cyclin/cdk2 and regulate interactions with E2F. Genes Dev. (1995) 9:1740–1752.
   PubMed Web of Science ®Google Scholar
• LUNDBERG AS, WEINBERG RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell. Biol. (1998) 18:753–761.
   PubMed Web of Science ®Google Scholar
• STIEGLER P, KASTEN M, GIORDANO A: The RB family of cell cycle regulatory factors. J. Cell. Biochem. Suppl. (1998) 30–31:30–36.
   PubMedGoogle Scholar
• •An interesting review on the partially distinct roles of the retinoblastoma family proteins in growth control, differen-tiation and apoptosis.
   Google Scholar
• THOMAS NSB, PIZZEY AR, TIWARI S, WILLIAMS CD, YANG J: p130, p107 and pRb are differentially regulated in proliferating cells and during cell cycle arrest by '(-interferon. j Biol Chem. (1998) 273: 23659–23667.
   PubMed Web of Science ®Google Scholar
• NEVINS JR: Toward an understanding of the functional complexity of the E2F and retinoblastoma families. Cell Growth Differ. (1998) 9:585–593.
   PubMedGoogle Scholar
• FLEMINGTON EK, SPECK SH, KAELIN WG, JR.: E2F1-mediated transactivation is inhibited by complex formation with the retinoblastoma suscepti-bility gene product. Proc. Natl. Acad. Sci. USA (1993) 90:6914–6918.
   PubMed Web of Science ®Google Scholar
• HELIN K, HARLOW E, FATTAEY A: Inhibition of F2F1 transactivation by direct binding of the retinoblas-toma protein. Mol Cell. Biol. (1993) 13:6501–6508.
   PubMed Web of Science ®Google Scholar
• SELLERS WR, RODGERS JW, KAELIN WG, JR.: A potent transrepression domain in the retinoblastomaprotein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA (1995) 92:11544–11548.
   PubMed Web of Science ®Google Scholar
• HARBOUR JVV, DEAN DC: Rb function in cell-cycle regulation and apoptosis. Nature Cell. Biol (2000) 2:65–67.
   PubMed Web of Science ®Google Scholar
• •An up-to-date review on the role of pRb/p105 in regulating apoptotic pathways.
   Google Scholar
• MORRIS L, ALLEN KE, LA THANGUE NB: Regulation of E2F transcription by cyclin E-Cdk2 kinase mediated through p 300 /CBP co-activators. Nature Cell Biol. (2000) 2:232–239.
   PubMed Web of Science ®Google Scholar
• STIEGLER P, GIORDANO A: Big brothers are watching: the retinoblastoma family and growth control. In: Molecular and Subcellular Biology. Marcello-Colheiro (Ed.), Springer-Verlag, New York, USA (1998):24–42.
   Google Scholar
• SELLER WR, KAELIN WG: Role of the retinoblastoma protein in the pathogenesis of human cancer. J. Clin. Oncol. (1997)1 5 :3301–3312.
   Google Scholar
• HOSHIKAWA Y, MORI A, AMIMOTO K, IWABE K, HATAKEYAMA M: Control of retinoblastoma protein-independent hematopoietic cell cycle by the pRB-related p130. Proc. Natl. Acad. Sci. USA (1998) 95:8574–8579.
   PubMed Web of Science ®Google Scholar
• MULLIGAN GJ, WONG J, JACKS T: p130 is dispensable in peripheral T lymphocytes: evidence for functional compensation by p107 and pRb. Mol. Cell Biol. (1998) 18:206–220.
   PubMed Web of Science ®Google Scholar
• HINDS PW, MITTNACHT S, DULIC V et al.: Regulation of retinoblastoma protein functions by ectopic expres-sion of human cyclins. Cell (1992) 70:993–1006.
   PubMed Web of Science ®Google Scholar
• LACY S, WHYTE P: Identification of p130 domain mediating interactions with cyclin A/cdk2 and cyclin E/cdk2 complexes. Oncogene (1997) 14:2395–2406.
   PubMed Web of Science ®Google Scholar
• HOWARD CM, CLAUDIO PP, GALLIA GL, GORDON J, GIORDANO A: Retinoblastoma-related protein pRb2/p130 and suppression of tumor growth in vivo. J. Nature Cancer Inst. (1998) 90:1415–1460.
   Google Scholar
• ZHU L, ENDERS G, LEES JA et al.: The pith-related proteinp107 contains two growth suppressor domains: independent interaction with E2F and cyclin/cdk complexes. EMBO J. (1995) 14:1904–1913.
   PubMed Web of Science ®Google Scholar
• JACOBSON MD, WEIL M, RAFF MC: Programmed cell death in animal development. Cell. (1997) 88:347–354.
   PubMed Web of Science ®Google Scholar
• EVAN JN, BROWN L, WHYTE M, HARRINGTON E: Apoptosis and cell death. CUIT. Opin. Cell Biol. (1995) 7: 825–834.
   Google Scholar
• ENOCH T, NORBURY C: Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci. (1995) 20:426–430.
   PubMed Web of Science ®Google Scholar
• LEVINE A: p53 the cellular gatekeeper for growth and division. Cell (1997) 88:323–331.
   PubMed Web of Science ®Google Scholar
• KASTEN MM, GIORDANO A: pill) and cdks in apoptosis and cell cycle. Cell Death Differ. (1998) 5:132–140.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on the role of pRb and the variouscyclin-dependent kinases in apoptosis.
   Google Scholar
• TSAI KY, HU Y, MACLEOD KF, CROWLEY D, YAMASAKI L, JACKS T: Mutation of F2F1 suppresses apoptosis and inappropriate S phase entry and extends survival of Rb-deficient mouse embryos. Mol Cell. (1998) 2:293–304.
   PubMed Web of Science ®Google Scholar
• HAAS-KOGAN DA, KOGAN SC, LEVI D et al: Inhibition of apoptosis by the retinoblastoma gene product. EMBOJ (1995) 14:461–472.
   PubMed Web of Science ®Google Scholar
• KRANENBURG O, VAN DER EB AJ, ZANTEMA A: Cyclin D1 is an essential mediator of neuronal cell death. EMBO J (1996) 15:46–54.
   PubMed Web of Science ®Google Scholar
• HAN EK, BEGEMANN M, SGAMBATO A et al: Increased expression of cyclin D1 in a murine mammary epithe-lial cell line induces 2716P1, inhibits growth and enhances apoptosis. Cell Growth Differ. (1996) 7:699–710.
   PubMedGoogle Scholar
• LAHTI JM, XIANG J, HEATH LS, CAMPANA D, KIDD J: PITSLRE protein kinase activity is associated with apoptosis. Mol. Cell. Biol. (1995) 15:1–11.
   PubMed Web of Science ®Google Scholar
• LEE MH, WILLIAMS BO, MULLIGAN G et al.: Targeted disruption of p107: functional overlap between p107 and Rb. Genes Dev. (1996) 16:1621–1632.
   Google Scholar
• WANG J, GUO K, WILLS KN, WALSH K: Rb functions to inhibit ap op tosis during myocyte differentiation. Cancer Res. (1997) 57:351–354.
   PubMed Web of Science ®Google Scholar
• CARNAC G, FAJAS L, L'HONORE A et al.: The retinoblastoma-like protein p130 is involved in the determination of reserve cells in differentiating myoblasts. Curr. Biol. (2000) 10:543-546.
   Google Scholar
• BALDI A, ESPOSITO V, DE LUCA A et al: Differential expression of pRb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin. Cancer. Res. (1997) 3:1691–1697.
   PubMed Web of Science ®Google Scholar
• MULLIGAN G, JACKS T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet. (1998) 14:223–229.
   PubMed Web of Science ®Google Scholar
• LEE EYHP, HU H, YUAN SSF et al.: Dual roles of the retinoblastoma protein in cell cycle regulation and neuron differentiation. Genes Dev. (1994) 8:2008–2021.
   PubMed Web of Science ®Google Scholar
• CALLAGHAN DA, DONG L, CALLAGHAN SM et al.: Neural precursor cells differentiating in the absence of Rb exhibit delayed terminal mitosis and deregulated F2F 1 and 3 activity. Dev. Biol (1999) 207:257–270.
   PubMed Web of Science ®Google Scholar
• LECOUTER JE, KABLAR B, WHYTE PF, YING C, RUDNICKI MA: Strain-dependent embryonic lethality in mice lacking the retinoblastoma-related p130 gene. Develop-ment (1998) 23:4669–4679.
   Google Scholar
• MORI A, HIGASHI H, HOSHIKAWA Y, IMAMURA M, ASAKA M, HATAKEYAMA M: Granulocytic differentia-tion of myeloid progenitor cells by p130, the retino-blastoma tumor suppressor homologue. Oncogene (1999) 18:6209–6221.
   PubMed Web of Science ®Google Scholar
• LI ZR, HROMCHAK R, MULTIPALLI A, BLOCH A: Tumor suppressor proteins as regulators of cell differentia-tion. Cancer. Res. (1998) 58:4282–4287.
   PubMed Web of Science ®Google Scholar
• RASCHELLA G, TANNO B, BONETTO F et al.: The Rb-related gene Rb2/p130 in neuroblastoma differen-tiation and in B-myb promoter down-regulation. Cell. Death Differ (1998) 5:401–407.
   PubMed Web of Science ®Google Scholar
• SHENG Q, LOVE TM, SCHAFFHAUSEN BJ: Domain-independent regulation of the Rb family by polyoma-virus large T antigen. J. Virol (2000) 74:5280–5290.
   PubMed Web of Science ®Google Scholar
• VOGELSTEIN B, KINZLER KW: The multistep nature of cancer. Trends Genet. (1993) 9:138–141.
   PubMed Web of Science ®Google Scholar
• HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumori-genesis. Cell (1996) 86:353–364.
   PubMed Web of Science ®Google Scholar
• RAK J, MITSUHASHI Y, SHEEHAN C et al.: Collateral expression of proangiogenic and tumorigenic proper-ties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia (1999) 1: 23–30.
   Google Scholar
• STIEGLER P, LOTAN R, GIORDANO A: From cell cycle regulation to angiogenesis: dialogue between the basic and clinical sciences. J. Cell. Physiol. (1999)179:233-236.
   Google Scholar
• ROBERTS DD: Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J. (1996) 10: 1183–1191.
   Google Scholar
• HOLMGREN L, JACKSON G, ARBISER J: p53 induces angiogenesis restricted dormancy in mouse fibrosar-coma. Oncogene (1998) 17:819–824.
   PubMed Web of Science ®Google Scholar
• DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regula-tion of thrombospondin-1. Science (1994) 265:1582–1584.
   PubMed Web of Science ®Google Scholar
• SALNIKOW K, COSENTINO S, KLEIN C, COSTA M: loss of thrombospondin transcriptional activity in nickel-transformed cells. Mol. Cell Biol. (1994) 14:851–858.
   PubMed Web of Science ®Google Scholar
• HARADA H, NAKAGAWA K, IWATA S et al: Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer. Res. (1999) 59:3783–3789.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, GRIFFITH EC, SAGE J et al.: Cell cycle inhibi-tion by the anti-angiogenic agent TNP-470 is mediated by p53 and p21 WAF1 /CIP1. Proc. Nati Acad. ScL USA (2000) 97:6427–6432.
   PubMed Web of Science ®Google Scholar
• HALL M, PETERS G: Genetic alterations of cyclins, cyclin-dependent kinases and Cdk inhibitors in human cancer. Adv. Cancer Res. (1996) 68:67–108.
   PubMed Web of Science ®Google Scholar
• KHATIB ZA, MATSUSHIME H, VALENTINE M, SHAPIRO DN, SHERR CJ, LOOK AT: Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res. (1993) 53:5535–5541.
   PubMed Web of Science ®Google Scholar
• HE J, ALLEN JR, COLLINS VP et al: CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. (1994) 54:5804–5807.
   PubMed Web of Science ®Google Scholar
• WOLFEL T, HAUER M, SCHNEIDER J et al.: A p16INK4 a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 269:1281–1214.
   PubMed Web of Science ®Google Scholar
• KOH J, ENDERS GH, DYNLACHT BD, HARLOW E: Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (1995) 375:506–510.
   PubMed Web of Science ®Google Scholar
• LUKAS J, PARRY D, AAGAARD L et al: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 375:503–506.
   PubMed Web of Science ®Google Scholar
• MINIMO C, BIBO M, CLAUDIO PP, DE LUCA A, GIORDANO A: The role of pRb2/p130 protein in diagnosing lung carcinoma on fine needle aspiration biopsies. Pathol Res. Pract. (1999) 195:67–70.
   PubMed Web of Science ®Google Scholar
• SUSINI T, BALDI F, HOWARD CM et al: Expression of the retinoblastoma related gene Rb2/p130 correlates with clinical outcome in endometrial cancer. J. Clin. Oncol. (1998)16:1085–1093.
   PubMed Web of Science ®Google Scholar
• MASSARO-GIORDANO M, BALDI G, DE LUCA A, BALDI A, GIORDANO A: Differential expression of the retino-blastoma gene family members in choroidal melanoma: prognostic significance. an. Cancer. Res. (1999) 5:1455–1458.
   Google Scholar
• LEONCINI L, BELLAN C, COSSU A et al: Retinoblastoma-related p107 and pRb2/p130 proteins in malignant lymphomas: distinct mechanisms of cell growth control. Clin. Cancer Res. (1999) 5:4065–4072.
   PubMed Web of Science ®Google Scholar
• ICHIMURA K, HANAFUSA H, TAKIMOTO1 H et al.: Structure of the human retinoblastoma-related p107 gene and its intragenic detection in a B-cell lymphoma cell line. Gene (2000) 251:37–43.
   PubMed Web of Science ®Google Scholar
• SALGIA R, SKARIN AT: Molecular abnormalities in lung cancer. J. Clin. Oncol (1998) 16:1207–1217.
   PubMed Web of Science ®Google Scholar
• ••An overview on genetic abnormalities involved inpathogenesis of lung cancer.
   Google Scholar
• SHIMIZU E, COXON A, OTTERSON GA et al: RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma and mesothelioma. Oncogene (1994) 9:2441–2448.
   PubMed Web of Science ®Google Scholar
• HELIN K, HOLM K, NIEBUHR A et al: LOSS of the retino-blastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. ScL USA (1997) 94:6933–6938.
   PubMed Web of Science ®Google Scholar
• SLAGIA R, SKARIN AT: Molecular abnormality in lung cancer. J. Clin. Oncol. (1998) 16:1207–1217.
   PubMed Web of Science ®Google Scholar
• DOSAKA-AKITA H, HU SX, FUJINO M et al.: Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer (1997) 79:1329–1337.
   PubMed Web of Science ®Google Scholar
• SHAPIRO GI, ROLLINS BJ: p16INK4A as a human tumor suppressor. Biochim. Biophys. Acta. (1996) 1242:165–169.
   PubMed Web of Science ®Google Scholar
• XU HJ, HU SX, CAGLE PT, MOORE GE, BENEDICT WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. (1991) 51:2735–2739.
   PubMed Web of Science ®Google Scholar
• BIGNON YJ, RIO P: The retinoblastoma gene: will therapeutic use of its tumor suppressor properties be possible? Bull. Cancer. (1993) 80:704–712.
   Web of Science ®Google Scholar
• ZUR HAUSEN H: Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta. (1996) 1288:F55–F78.
   PubMed Web of Science ®Google Scholar
• PROCOPIO A, STRIZZI L, GIUFFRIDA A et al: Human malignant mesothelioma of the pleura: new perspec-tives for diagnosis and therapy. Monaldi Arch. Chest. Dis. (1998) 53:241–243.
   PubMedGoogle Scholar
• MUTTI L, DE LUCA A, CLAUDIO PP et al.: Simian virus 40-like DNA sequences and large-T antigen-retinoblastoma family protein pRb2/p130 interaction in human mesothelioma. Dev. Biol. Stand. (1998) 9:47–53.
   Google Scholar
• PUPA SM, HOWARD CM, INVERNIZZI AM et al.: Ectopic expression of pRb2/p130 suppresses the tumorigen-icity of the c-erbB-2-overexpressing SKOV3 tumor cell Oncogene (1999) 18:651–656.
   PubMed Web of Science ®Google Scholar
• PARR MJ, MANOME Y, TANAKA T et al: Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nature Med. (1997) 3:1145–1149.
   PubMed Web of Science ®Google Scholar
• •This paper shows that viral vectors containing E2F-responsive promoters could be useful to selectively express suicide genes in cancer cells.
   Google Scholar